Stock Ratings / Health Care / CRIS / options

PMCB (40) LIMN (45) CELZ (27) BTTC (48) ⌘ Pro Terminal →

Curis Inc. (CRIS) Options Positioning, Max Pain & Unusual Sweeps

$0.55 +20.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.57

Curis Inc. (CRIS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.57 (+3.56%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRIS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY CRIS SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (28% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 42.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.67-38.8% Next Q

Q2 (-2Q)

Grade D$0.41-4.9% Next Q

Q3 (-1Q)

Grade D$0.39+41% Next Q

Current

Grade D-$0.55-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRIS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRIS currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.92) and Max Pain ($0.58) forces dealer call-delta covering toward $33.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRIS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRIS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CRIS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CRIS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRIS)

✓Walkthrough of CRIS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRIS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -95.42%📐 HORIZONTAL RANGE

2026-10-30O $0.55H $0.65L $0.47C $0.55VOL 913.2K

SUP: $-5.07SMA50: $0.92SMA200: $9.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRIS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRIS Butterfly Map → + Track CRIS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -13.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRIS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRIS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRIS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRIS)

Health Care Rank #656 of 1016 ⚔️ PMCB vs CRIS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRIS vs. PMCB, LIMN, CELZ, BTTC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Curis Inc. (CRIS) ranks #656 by composite RQD confidence (40/100, grade D-) and #967 by equity capitalization ($3.7M). Within this direct 5-issuer industry benchmark cohort, CRIS leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with CRIS at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRIS ACTIVE Curis Inc.	D-	40/100	—	—	-35.0%	+20.82%	$3.7M	Benchmark Subject
PMCB PharmaCyte Biotech Inc.	D-	40/100	—	—	-30.2%	-0.78%	$3.6M	/pmcb-vs-cris →
LIMN Liminatus Pharma Inc. (Class A)	D	45/100	—	—	-35.0%	-0.86%	$3.9M	/limn-vs-cris →
CELZ Creative Medical Technology Holdings Inc.	E	27/100	—	63.4%	-35.0%	-5.78%	$5.2M	/celz-vs-cris →
BTTC Black Titan Corporation	D	48/100	—	—	—	+4.23%	$5.3M	/bttc-vs-cris →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001108205

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Curis Inc. (CRIS) reported GAAP revenue of $9.4M (-13.4% vs. FY2024 revenue of $10.9M , and -5.8% cumulative change since FY2023) , GAAP net income of -$7.6M, operating cash flow of -$27.2M, and free cash flow of -$27.2M (+31.2% YoY). On the balance sheet, CRIS closed FY2025 with $20.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.4M	-$7.6M	-$27.2M	-$27.2M	$20.0M	—
FY2024 (FY)	2024-12-31	$10.9M	-$43.4M	-$39.6M	-$39.6M	$41.3M	—
FY2023 (FY)	2023-12-31	$10.0M	-$47.4M	-$38.4M	-$38.4M	—	—

3. CRIS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRIS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Curis Inc. (NASDAQ: CRIS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.55 (+20.82% 1D, market cap $3.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRIS ranks #656 in composite RQD confidence.

How does CRIS compare to PMCB and LIMN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRIS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMCB (PharmaCyte Biotech Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -30.2%, cap $3.6M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, CRIS leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRIS?

Per CRIS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001108205), Curis Inc. generated $9.4M in revenue (-13.4% YoY), -$7.6M in net income, and -$27.2M in free cash flow against $20.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRIS trading relative to its 50-day, 200-day, and 52-week technical levels?

CRIS last traded at $0.55 (+20.82% on volume of 6,414,213 shares), positioning the stock -40.22% below its 50-day simple moving average ($0.92) and -93.92% below its 200-day simple moving average ($9.04). Across its 52-week range of $0.33 to $31.80, CRIS sits at the 0.7% percentile with a 14-day RSI of 42.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.62).